Terms: = Lymphoma AND FH, HLRCC, 2271, ENSG00000091483, MCUL1, MCL, LRCC, P07954
3282 results:
1. SOX11 is a novel binding partner and endogenous inhibitor of SAMHD1 ara-CTPase activity in mantle cell lymphoma.
Morsy MHA; Lilienthal I; Lord M; Merrien M; Wasik AM; Sureda-Gómez M; Amador V; Johansson HJ; Lehtiö J; Garcia-Torre B; Martin-Subero JI; Tsesmetzis N; Tao S; Schinazi RF; Kim B; Sorteberg AL; Wickström M; Sheppard D; Rassidakis GZ; Taylor IA; Christensson B; Campo E; Herold N; Sander B
Blood; 2024 Jan; 143(19):1953-1964. PubMed ID: 38774451
[TBL] [Abstract] [Full Text] [Related]
2. Outcomes of pirtobrutinib for relapsed/refractory mantle cell lymphoma in compassionate use program in Europe.
Aydilek E; Wulf G; Schwarz F; Bacher U; Rummel M; Stiefel O; Kerkhoff A; Maulhardt M; Melchardt T; Pabst T; Lenz G; Shumilov E
Cancer Med; 2024 May; 13(10):e7289. PubMed ID: 38770551
[TBL] [Abstract] [Full Text] [Related]
3. In Vivo, In Vitro and In Silico Anticancer Activity of Ilama Leaves: An Edible and Medicinal Plant in Mexico.
Ramírez-Santos J; Calzada F; Ordoñez-Razo RM; Mendieta-Wejebe JE; Velázquez-Domínguez JA; Argüello-García R; Velázquez C; Barbosa E
Molecules; 2024 Apr; 29(9):. PubMed ID: 38731446
[TBL] [Abstract] [Full Text] [Related]
4. Inhibition of SRC-3 as a potential therapeutic strategy for aggressive mantle cell lymphoma.
Bijou I; Liu Y; Lu D; Chen J; Sloan S; Alinari L; Lonard DM; O'Malley BW; Wang M; Wang J
PLoS One; 2024; 19(4):e0289902. PubMed ID: 38683834
[TBL] [Abstract] [Full Text] [Related]
5. Treatment patterns, clinical outcomes and gene mutation characteristics of hepatitis B virus-associated mantle cell lymphoma.
Feng J; Fei Y; Gao M; Meng X; Zeng D; Zou D; Ye H; Liang Y; Sun X; Liang R; Zhou H; Wang X; Zhang H
Hematol Oncol; 2024 May; 42(3):e3268. PubMed ID: 38676394
[TBL] [Abstract] [Full Text] [Related]
6. [Inhibition of Autophagy Augments the Anticancer Activity of KPT-330 in Mantle Cell lymphoma Cells].
Zhang YL; Chen YH; Zheng RJ; Zheng KJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):470-475. PubMed ID: 38660854
[TBL] [Abstract] [Full Text] [Related]
7. Noncoding RNAs in B cell non-Hodgkins lymphoma.
Abedi Kichi Z; Dini N; Rojhannezhad M; Shirvani Farsani Z
Gene; 2024 Jul; 917():148480. PubMed ID: 38636814
[TBL] [Abstract] [Full Text] [Related]
8. MNDA expression and its value in differential diagnosis of B-cell non-Hodgkin lymphomas: a comprehensive analysis of a large series of 1293 cases.
Zhang LF; Zhang Y; Shui RH; Lu HF; Jiang WH; Cai X; Li XQ; Yu BH
Diagn Pathol; 2024 Apr; 19(1):60. PubMed ID: 38627702
[TBL] [Abstract] [Full Text] [Related]
9. PRMT5 activates lipid metabolic reprogramming via MYC contributing to the growth and survival of mantle cell lymphoma.
Liang JH; Wang WT; Wang R; Gao R; Du KX; Duan ZW; Zhang XY; Li Y; Wu JZ; Yin H; Shen HR; Wang L; Li JY; Guo JR; Xu W
Cancer Lett; 2024 Jun; 591():216877. PubMed ID: 38615930
[TBL] [Abstract] [Full Text] [Related]
10. Covalent docking-driven virtual screening of extensive small-molecule libraries against Bruton tyrosine kinase for the identification of highly selective and potent novel therapeutic candidates.
Sambur E; Oktay L; Durdağı S
J Mol Graph Model; 2024 Jul; 130():108762. PubMed ID: 38614067
[TBL] [Abstract] [Full Text] [Related]
11. Targeting Myeloid Leukemia-1 in Cancer Therapy: Advances and Directions.
Deng H; Han Y; Liu L; Zhang H; Liu D; Wen J; Huang M; Zhao L
J Med Chem; 2024 Apr; 67(8):5963-5998. PubMed ID: 38597264
[TBL] [Abstract] [Full Text] [Related]
12. SOX11/PRDX2 axis modulates redox homeostasis and chemoresistance in aggressive mantle cell lymphoma.
De Bolòs A; Sureda-Gómez M; Carreras-Caballé M; Rodríguez ML; Clot G; Beà S; Giné E; Campo E; Balsas P; Amador V
Sci Rep; 2024 Apr; 14(1):7863. PubMed ID: 38570586
[TBL] [Abstract] [Full Text] [Related]
13. Empowering macrophages: the cancer fighters within the tumour microenvironment in mantle cell lymphoma.
Nylund P; Nikkarinen A; Ek S; Glimelius I
Front Immunol; 2024; 15():1373269. PubMed ID: 38566987
[TBL] [Abstract] [Full Text] [Related]
14. Phase 1/2 multicenter trial of acalabrutinib in Chinese patients with relapsed/refractory mantle cell lymphoma.
Song Y; Li J; Zhou K; Ke X; Cai Z; Zhang H; Yao T; Xia Z; Wang Y; Lai P; Liu X; Zhu J
Leuk Lymphoma; 2024 May; 65(5):647-652. PubMed ID: 38557285
[TBL] [Abstract] [Full Text] [Related]
15. Targeting DNMT3A-mediated oxidative phosphorylation to overcome ibrutinib resistance in mantle cell lymphoma.
Hoang NM; Liu Y; Bates PD; Heaton AR; Lopez AF; Liu P; Zhu F; Chen R; Kondapelli A; Zhang X; Selberg PE; Ngo VN; Skala MC; Capitini CM; Rui L
Cell Rep Med; 2024 Apr; 5(4):101484. PubMed ID: 38554704
[TBL] [Abstract] [Full Text] [Related]
16. BCL-2 inhibition in haematological malignancies: Clinical application and complications.
Fowler-Shorten DJ; Hellmich C; Markham M; Bowles KM; Rushworth SA
Blood Rev; 2024 May; 65():101195. PubMed ID: 38523032
[TBL] [Abstract] [Full Text] [Related]
17. Metabolic and toxicological considerations of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.
Wolska-Washer A; Robak P; Witkowska M; Robak T
Expert Opin Drug Metab Toxicol; 2024 Apr; 20(4):207-224. PubMed ID: 38516702
[TBL] [Abstract] [Full Text] [Related]
18. B-cell receptor signaling activity identifies patients with mantle cell lymphoma at higher risk of progression.
Gambino S; Quaglia FM; Galasso M; Cavallini C; Chignola R; Lovato O; Giacobazzi L; Caligola S; Adamo A; Putta S; Aparo A; Ferrarini I; Ugel S; Giugno R; Donadelli M; Dando I; Krampera M; Visco C; Scupoli MT
Sci Rep; 2024 Mar; 14(1):6595. PubMed ID: 38503806
[TBL] [Abstract] [Full Text] [Related]
19. Safety and efficacy of zandelisib plus zanubrutinib in previously treated follicular and mantle cell lymphomas.
Soumerai JD; Diefenbach CS; Jagadeesh D; Asch A; Kumar A; Tsai ML; Jandl TA; Lossos IS; Kenkre VP; Awan F; Novotny W; Huang J; Miao L; Rajagopalan P; Ghalie RG; Zelenetz AD
Br J Haematol; 2024 May; 204(5):1762-1770. PubMed ID: 38500476
[TBL] [Abstract] [Full Text] [Related]
20. Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor.
Salles G; Chen JMH; Zhang I; Kerbauy F; Wu JJ; Wade SW; Nunes A; Feng C; Kloos I; Peng W; Snider JT; Maciel D; Chan K; Keeping S; Shah B
Adv Ther; 2024 May; 41(5):1938-1952. PubMed ID: 38494543
[TBL] [Abstract] [Full Text] [Related]
[Next]
